QUOTE AND NEWS
Motley Fool  Nov 10  Comment 
MannKind's long-awaited inhaled insulin product is nearing a commercial launch. The drug may be in for a bumpier ride than most expect, however. Here's why.
SeekingAlpha  Nov 8  Comment 
Motley Fool  Nov 4  Comment 
Earnings aren't nearly as important as MannKind's cash in the bank.
newratings.com  Nov 3  Comment 
WASHINGTON (dpa-AFX) - MannKind Corp (MNKD), a development stage biopharmaceutical company, Monday reported third-quarter net loss of $36.5 million or $0.09 per share compared with a loss of $50.8 million or $0.17 per share last year. Analysts...
DailyFinance  Nov 3  Comment 
Filed under: Company News, Earnings, Market News, Investing Ben Margot/AP From the leading maker of premium plug-in sedans pulling in for its quarterly pit stop to an update on a fast-growing portal making bigger waves overseas than it is close...




 

MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.

Competition

MannKind's primary competitors include:

References

  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki